精准肿瘤学市场 - 全球产业规模、份额、趋势、机会和预测，按产品类型、癌症类型、最终用户区域和竞争细分，2019-2029F

2023 年全球精准肿瘤市场价值为971.2 亿美元，预计到2029 年，预测期内将实现强劲增长，复合年增长率为9.01%。客製化治疗解决癌症复杂性和多样性的疗法。精准肿瘤学根据基因组成、肿瘤特征和分子因素为个人量身定制医疗护理，旨在优化治疗效果，同时最大限度地减少副作用。在基因组学、分子生物学、生物资讯学和人工智慧进步的推动下，市场经历了显着的成长。主要市场驱动因素包括全球癌症发病率上升、患者和医疗保健提供者对个人化医疗益处的认识不断提高，以及标靶治疗和伴随诊断的广泛应用。采用液体活检技术进行非侵入性肿瘤监测和治疗反应评估也有助于市场扩张。

市场概况
预测期	2025-2029
2023 年市场规模	971.2亿美元
2029 年市场规模	1633.4亿美元
2024-2029 年复合年增长率	9.01%
成长最快的细分市场	乳癌
最大的市场	北美洲

此外，巨量资料分析和机器学习演算法的整合改进了复杂的基因组资料解释，有助于识别可操作的生物标记并开发创新的治疗方法。製药公司越来越多地投资于精准肿瘤学研发，与诊断公司和学术机构合作发现生物标记并验证治疗标靶。监管机构也简化了标靶治疗和伴随诊断的审批流程，促进精准肿瘤学的创新。儘管如此，高昂的基因组测试成本、有限的报销政策以及某些地区的监管复杂性等挑战阻碍了市场的成长。

确保强大的资料隐私和安全措施对于道德和负责任地利用患者基因组资讯仍然至关重要。展望未来，在持续的技术进步、各种癌症类型的更广泛应用以及向优先考虑个人化治疗策略的基于价值的医疗模式转变的推动下，全球精准肿瘤学市场将持续增长。随着精准肿瘤学的发展，它有望透过改善患者的治疗效果、最大限度地减少与治疗相关的不良反应，并有可能将癌症转变为许多患者可控制的慢性疾病，从而彻底改变癌症治疗。

主要市场驱动因素

基因组学和分子生物学的进展

全球癌症盛行率不断上升

标靶治疗和伴随诊断的兴起

主要市场挑战

有限报销政策

监管障碍和合规性

资料隐私和安全问题

主要市场趋势

基因体分析技术的进步

液体切片的兴起

细分市场洞察

产品类型见解

癌症类型见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球精准肿瘤学市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依产品类型（诊断、治疗）
  • 依癌症类型（乳癌、子宫颈癌、摄护腺癌、肺癌）
  • 按最终用户（医院和诊断实验室、製药和生物技术公司、医疗保健数据公司）
  • 按地区
  • 按公司划分 (2023)
• 市场地图
  • 依产品类型
  • 按癌症类型
  • 按最终用户
  • 按地区

第 6 章：亚太地区精准肿瘤学市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依产品类型
  • 按癌症类型
  • 按最终用户
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 7 章：欧洲精准肿瘤学市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依产品类型
  • 按癌症类型
  • 按最终用户
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 8 章：北美精准肿瘤市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依产品类型
  • 按癌症类型
  • 按最终用户
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 9 章：南美洲精准肿瘤市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依产品类型
  • 按癌症类型
  • 按最终用户
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲精准肿瘤学市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依产品类型
  • 按癌症类型
  • 按最终用户
  • 按国家/地区
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 埃及

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 最近的发展
• 产品发布（如有）
• 併购（如有）

第 13 章：全球精准肿瘤学市场：SWOT 分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第15章：竞争格局

• Thermo Fisher Scientific Inc.
• Invitae Corporation
• Qiagen NV
• Illumina, Inc.
• Laboratory Corporation Of America Holding
• Exact Sciences Corporation
• Rain Oncology Inc.
• Strata Oncology, Inc.
• Xilis, Inc.
• Variantyx, Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

Global Precision Oncology Market was valued at USD 97.12 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 9.01% through 2029. The Global Precision Oncology Market signifies a significant transformation in cancer treatment, utilizing advanced technologies and customized therapies to address cancer's complexity and diversity. Precision oncology tailors medical care to individuals based on genetic makeup, tumor characteristics, and molecular factors, aiming to optimize treatment effectiveness while minimizing side effects. The market has experienced notable growth driven by advancements in genomics, molecular biology, bioinformatics, and artificial intelligence. Key market drivers include the rising global cancer incidence, increased awareness among patients and healthcare providers about personalized medicine benefits, and wider availability of targeted therapies and companion diagnostics. The adoption of liquid biopsy techniques for non-invasive tumor monitoring and treatment response assessment has also contributed to market expansion.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 97.12 Billion
Market Size 2029	USD 163.34 Billion
CAGR 2024-2029	9.01%
Fastest Growing Segment	Breast Cancer
Largest Market	North America

Also, the integration of big data analytics and machine learning algorithms has improved complex genomic data interpretation, aiding in identifying actionable biomarkers and developing innovative therapeutic approaches. Pharmaceutical firms are increasingly investing in precision oncology R&D, collaborating with diagnostic companies and academic institutions to discover biomarkers and validate therapeutic targets. Regulatory agencies are also simplifying approval processes for targeted therapies and companion diagnostics, fostering innovation in precision oncology. Nonetheless, challenges such as high genomic testing costs, limited reimbursement policies, and regulatory complexities in some regions hinder market growth.

Ensuring robust data privacy and security measures remains crucial to ethically and responsibly utilize patients' genomic information. Looking ahead, the global precision oncology market is poised for continued growth, driven by ongoing technological advancements, broader applications across various cancer types, and a shift towards value-based healthcare models prioritizing personalized treatment strategies. As precision oncology evolves, it promises to revolutionize cancer care by enhancing patient outcomes, minimizing treatment-related adverse effects, and potentially turning cancer into a manageable chronic condition for many patients.

Key Market Drivers

Advancements in Genomics and Molecular Biology

Advancements in genomics and molecular biology have played a pivotal role in driving the growth of the global precision oncology market, revolutionizing our understanding of cancer biology and treatment strategies. Genomics, the study of an organism's complete set of DNA, and molecular biology, the study of molecular processes within cells, have provided unprecedented insights into the genetic mutations and molecular pathways underlying cancer development and progression. One of the key advancements in genomics that has catalyzed progress in precision oncology is the advent of next-generation sequencing (NGS) technologies. NGS enables rapid and cost-effective sequencing of entire genomes, allowing researchers and clinicians to comprehensively profile the genetic alterations present in cancer cells. This deep molecular characterization of tumors facilitates the identification of specific driver mutations, oncogenic pathways, and actionable biomarkers that can guide treatment decisions.

Also, the development of high-throughput genomic profiling techniques has expanded our ability to interrogate the cancer genome at a finer resolution. Techniques such as whole-exome sequencing (WES) and RNA sequencing (RNA-seq) provide detailed information about coding and non-coding regions of the genome, as well as gene expression patterns, splice variants, and fusion events. This wealth of genomic data enables researchers to unravel the molecular complexity of cancer and identify novel therapeutic targets with precision.

In addition to genomics, advancements in molecular biology have contributed to the burgeoning field of precision oncology. Techniques such as polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), and immunohistochemistry (IHC) allow for the detection and characterization of specific genetic alterations and protein expression patterns in tumor samples. These molecular assays serve as valuable tools for diagnosing cancer subtypes, predicting treatment responses, and monitoring disease progression.

The integration of molecular profiling data with clinical outcomes has facilitated the development of predictive biomarkers and personalized treatment algorithms in oncology. By correlating genomic alterations with treatment responses and patient outcomes, researchers can identify biomarker signatures associated with drug sensitivity or resistance, enabling the stratification of patients into subgroups that are most likely to benefit from specific targeted therapies.

Growing Prevalence of Cancer Worldwide

The growing prevalence of cancer worldwide is a significant driver behind the expansion of the global precision oncology market. Over the past few decades, cancer has emerged as one of the leading causes of morbidity and mortality globally, with incidence rates steadily rising across all regions and demographics. This increasing burden of cancer underscores the urgent need for more effective and personalized treatment approaches, driving the demand for precision oncology solutions.

Several factors contribute to the growing prevalence of cancer worldwide. Aging populations, changing lifestyle habits, environmental factors, and the increasing prevalence of risk factors such as obesity and tobacco use all contribute to the rising incidence of cancer. Additionally, improvements in screening and diagnostic technologies have led to earlier detection of cancer, resulting in higher reported incidence rates. As a result, healthcare systems worldwide are grappling with the challenge of managing a growing number of cancer cases and the associated healthcare costs.

Precision oncology offers a promising solution to address the complex and heterogeneous nature of cancer. By leveraging advanced genomic profiling techniques, molecular biomarkers, and targeted therapies, precision oncology enables clinicians to tailor treatment strategies to the unique genetic makeup and molecular characteristics of individual tumors. This personalized approach holds the potential to improve treatment outcomes, minimize adverse effects, and enhance the overall quality of life for cancer patients.

Also, the expanding applications of precision oncology across different cancer types further contribute to its growing adoption worldwide. While initially focused on certain cancer types with well-defined molecular targets, precision oncology is now being applied across a broader spectrum of malignancies, including rare and refractory cancers. Advances in genomic profiling and biomarker discovery have facilitated the identification of new therapeutic targets and predictive biomarkers, enabling the development of targeted therapies and companion diagnostics for a diverse range of cancers.

Rise of Targeted Therapies and Companion Diagnostics

The rise of targeted therapies and companion diagnostics has significantly contributed to the growth and advancement of the global precision oncology market. Targeted therapies are a class of cancer treatments designed to specifically target molecular alterations or pathways that drive tumor growth and progression. Unlike traditional chemotherapy, which often indiscriminately kills rapidly dividing cells, targeted therapies aim to selectively inhibit the activity of cancer-causing proteins or pathways while sparing healthy cells.

Companion diagnostics play a crucial role in precision oncology by identifying patients who are most likely to benefit from specific targeted therapies based on the presence of specific biomarkers or molecular alterations in their tumors. These diagnostic tests help clinicians personalize treatment decisions, ensuring that patients receive the most appropriate therapy for their unique molecular profile. By pairing targeted therapies with companion diagnostics, clinicians can optimize treatment efficacy, minimize adverse effects, and improve patient outcomes.

The development of targeted therapies and companion diagnostics has been facilitated by advances in genomic sequencing technologies and our growing understanding of the molecular mechanisms underlying cancer. Next-generation sequencing (NGS) and other molecular profiling techniques enable comprehensive characterization of tumors, allowing researchers to identify driver mutations, oncogenic pathways, and actionable biomarkers. Armed with this knowledge, pharmaceutical companies can develop targeted drugs that specifically inhibit the activity of these molecular targets.

One of the key advantages of targeted therapies is their ability to deliver more precise and effective treatment while minimizing off-target effects. By selectively targeting cancer cells with specific molecular vulnerabilities, targeted therapies have the potential to achieve higher response rates and prolonged disease control compared to conventional chemotherapy. This precision approach not only improves patient outcomes but also reduces the likelihood of treatment-related toxicities and adverse effects.

Also, the growing availability of targeted therapies and companion diagnostics has expanded treatment options for patients across a wide range of cancer types. While initially developed for certain cancers with well-defined molecular targets, such as HER2-positive breast cancer or BRAF-mutant melanoma, targeted therapies are now being explored in a variety of malignancies, including lung cancer, colorectal cancer, and hematologic malignancies.

Key Market Challenges

Limited Reimbursement Policies

A significant barrier to the widespread adoption of precision oncology is the limited reimbursement policies for molecular profiling tests and targeted therapies. While these innovative technologies hold promise for improving patient outcomes, their high costs pose financial challenges for patients, healthcare providers, and payers alike. Many insurers have yet to establish clear guidelines for reimbursing molecular profiling tests and targeted therapies, leading to disparities in access to precision oncology services. Additionally, the lack of standardized reimbursement processes complicates the financial landscape for healthcare providers, who may hesitate to invest in precision oncology technologies without assurance of reimbursement. Addressing this challenge requires collaboration among stakeholders to develop transparent reimbursement policies that ensure equitable access to precision oncology services for all patients.

Regulatory Hurdles and Compliance

The development and commercialization of precision oncology products, including molecular profiling tests and targeted therapies, are subject to rigorous regulatory scrutiny by health authorities worldwide. Obtaining regulatory approval for these products can be a lengthy and complex process, requiring extensive clinical validation, evidence of safety and efficacy, and adherence to quality standards. Furthermore, the regulatory landscape for precision oncology is constantly evolving, with new guidelines and requirements emerging as technologies advance and new therapeutic approaches are developed. Navigating these regulatory hurdles presents a formidable challenge for industry stakeholders, requiring substantial investments of time, resources, and expertise. Additionally, achieving compliance with regulatory requirements is essential for ensuring patient safety and maintaining public trust in precision oncology technologies. Collaborative efforts among regulators, industry stakeholders, and healthcare providers are needed to streamline the regulatory process and facilitate the timely approval and adoption of innovative precision oncology products.

Data Privacy and Security Concerns

A critical challenge facing the global precision oncology market is data privacy and security concerns associated with the collection, storage, and sharing of genomic and clinical data. Precision oncology relies on the analysis of large volumes of sensitive patient information, including genomic sequencing data, medical records, and treatment histories. Protecting this data from unauthorized access, breaches, and misuse is paramount to safeguarding patient privacy and maintaining trust in precision oncology technologies. However, ensuring data privacy and security is a complex and multifaceted challenge that requires robust technical, organizational, and regulatory measures. Healthcare organizations must implement stringent data protection policies, encryption protocols, and access controls to safeguard patient data throughout its lifecycle.

Key Market Trends

Advancements in Genomic Profiling Technologies

Advancements in genomic profiling technologies have emerged as a driving force behind the rapid growth and expansion of the global precision oncology market. Genomic profiling, which involves the comprehensive analysis of an individual's genetic makeup, holds immense promise for understanding the molecular basis of cancer and tailoring treatment strategies to target specific genetic alterations. As genomic profiling technologies continue to evolve, they are revolutionizing the field of precision oncology and transforming cancer care on a global scale. Next-generation sequencing (NGS) has emerged as a cornerstone technology in genomic profiling, enabling researchers and clinicians to analyze the entire genome, exome, or specific regions of interest with unprecedented speed and accuracy. NGS allows for the detection of genetic mutations, copy number variations, and chromosomal rearrangements that drive cancer development and progression. By sequencing tumor DNA and comparing it to the patient's germline DNA, clinicians can identify somatic mutations that are specific to the tumor, providing valuable insights into its molecular profile and potential vulnerabilities.

In addition to NGS, other genomic profiling technologies, such as microarray-based assays and digital PCR, are also contributing to the advancement of precision oncology. Microarray-based assays allow for the simultaneous analysis of thousands of genetic markers, enabling researchers to identify gene expression patterns, epigenetic alterations, and protein interactions associated with cancer biology. Digital PCR, on the other hand, offers high sensitivity and specificity for detecting rare mutations and measuring allele frequencies in tumor samples, providing valuable information for treatment selection and monitoring.

The integration of genomic profiling technologies into clinical practice is driving the development of targeted therapies and companion diagnostics that are tailored to the molecular characteristics of individual tumors. By identifying specific genetic alterations or biomarkers that drive tumor growth, clinicians can select targeted therapies that inhibit these molecular pathways, leading to more effective and personalized treatment regimens. Companion diagnostics play a crucial role in precision oncology by identifying patients who are most likely to benefit from targeted therapies based on the presence of specific biomarkers in their tumors.

Rise of Liquid Biopsies

The rise of liquid biopsies has emerged as a significant driver in boosting the global precision oncology market, offering a non-invasive and comprehensive approach to cancer detection, monitoring, and treatment. Liquid biopsies involve the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers present in blood or other bodily fluids. This innovative technology has revolutionized cancer care by providing real-time insights into tumor dynamics and treatment response, ultimately enhancing the delivery of personalized treatment strategies.

One of the key advantages of liquid biopsies is their non-invasive nature, which eliminates the need for traditional tissue biopsies that can be invasive, costly, and associated with potential risks and complications. By analyzing ctDNA and CTCs shed from primary tumors or metastatic sites into the bloodstream, liquid biopsies enable clinicians to obtain comprehensive molecular information about the tumor without the need for invasive procedures. This non-invasive approach is particularly valuable for patients who are unable to undergo surgical biopsy or have tumors located in challenging anatomical locations.

Liquid biopsies also offer the advantage of real-time monitoring of tumor evolution and treatment response, allowing clinicians to detect early signs of disease progression or treatment resistance. By serially sampling blood or other bodily fluids over the course of treatment, clinicians can track changes in the tumor's molecular profile and adjust treatment regimens accordingly. This dynamic monitoring approach enables more timely interventions and optimization of treatment strategies, ultimately improving patient outcomes and survival rates.

Moreover, liquid biopsies provide a more comprehensive assessment of tumor heterogeneity and molecular subtypes compared to traditional tissue biopsies, which may only capture a small portion of the tumor. By analyzing ctDNA and CTCs shed from multiple tumor sites, liquid biopsies offer a more representative snapshot of the tumor's genetic landscape, enabling the identification of targetable mutations and personalized treatment options.

Segmental Insights

Product Type Insights

Based on the product type, therapeutics segment emerged as the dominant segment in the global precision oncology market in 2023. Advancements in genomic profiling technologies have led to the identification of novel therapeutic targets and the development of targeted therapies tailored to individual tumor characteristics. By analyzing the genetic mutations and molecular pathways driving cancer development, precision oncology therapeutics can selectively inhibit the activity of cancer-causing proteins or pathways while sparing healthy cells, leading to improved treatment efficacy and fewer adverse effects.

Cancer Type Insights

Based on the cancer type, breast cancer segment emerged as the dominant segment in the Global Precision Oncology market in 2023. Breast cancer is one of the most prevalent cancers worldwide, affecting millions of individuals each year. The high incidence of breast cancer has spurred significant research and development efforts focused on improving treatment outcomes and patient survival rates. Precision oncology offers tailored therapies that target specific genetic mutations and molecular pathways implicated in breast cancer development and progression, leading to more effective and personalized treatment strategies.

Regional Insights

North America emerged as the dominant player in the global precision oncology market in 2023, holding the largest market share. North America boasts a robust healthcare infrastructure with advanced medical research facilities, leading academic institutions, and a well-established pharmaceutical industry. This conducive environment fosters innovation and collaboration among healthcare stakeholders, driving the development and adoption of precision oncology technologies and therapies.

Key Market Players

Thermo Fisher Scientific Inc.

Invitae Corporation

Qiagen N.V.

Illumina, Inc.

Laboratory Corporation Of America Holding

Exact Sciences Corporation

Rain Oncology Inc.

Strata Oncology, Inc.

Xilis Inc.

Variantyx, Inc.

Report Scope:

In this report, the Global Precision Oncology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Precision Oncology Market, By Product Type:

Diagnostics Therapeutics

Precision Oncology Market, By Cancer Type:

Breast Cancer Cervical Cancer Prostate Cancer Lung Cancer

Precision Oncology Market, By End User:

Hospitals & Diagnostic Laboratories Pharmaceutical & Biotechnology Companies Healthcare Data Companies

Precision Oncology Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Precision Oncology Market.

Available Customizations:

Global Precision Oncology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Precision Oncology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Diagnostics, Therapeutics)
  • 5.2.2. By Cancer Type (Breast Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer)
  • 5.2.3. By End User (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Healthcare Data Companies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Product Type
  • 5.3.2. By Cancer Type
  • 5.3.3. By End User
  • 5.3.4. By Region

6. Asia Pacific Precision Oncology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Cancer Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Precision Oncology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Cancer Type
      • 6.3.1.2.3. By End User
  • 6.3.2. India Precision Oncology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Cancer Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Precision Oncology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Cancer Type
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Precision Oncology Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product Type
      • 6.3.4.2.2. By Cancer Type
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Precision Oncology Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product Type
      • 6.3.5.2.2. By Cancer Type
      • 6.3.5.2.3. By End User

7. Europe Precision Oncology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Cancer Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Precision Oncology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Cancer Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Precision Oncology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Cancer Type
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Precision Oncology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Cancer Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Precision Oncology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Cancer Type
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Precision Oncology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Cancer Type
      • 7.3.5.2.3. By End User

8. North America Precision Oncology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Cancer Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Precision Oncology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Cancer Type
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Precision Oncology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Cancer Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Precision Oncology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Cancer Type
      • 8.3.3.2.3. By End User

9. South America Precision Oncology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Cancer Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Precision Oncology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Cancer Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Precision Oncology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Cancer Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Precision Oncology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Cancer Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Precision Oncology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Cancer Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Precision Oncology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Cancer Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Precision Oncology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Cancer Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Precision Oncology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Cancer Type
      • 10.3.3.2.3. By End User
  • 10.3.4. Egypt Precision Oncology Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Product Type
      • 10.3.4.2.2. By Cancer Type
      • 10.3.4.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches (If Any)
• 12.3. Mergers & Acquisitions (If Any)

13. Global Precision Oncology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Invitae Corporation
• 15.3. Qiagen N.V.
• 15.4. Illumina, Inc.
• 15.5. Laboratory Corporation Of America Holding
• 15.6. Exact Sciences Corporation
• 15.7. Rain Oncology Inc.
• 15.8. Strata Oncology, Inc.
• 15.9. Xilis, Inc.
• 15.10. Variantyx, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer